For 2021, the level of MDM for office/outpatient E/Ms continues to be based on
2 out of 3 elements:
1) Problems Addressed
2) Data Reviewed and Analyzed
3) Risk
In terms of problems addressed, a level four visit requires:
1 or more chronic illnesses with exacerbation, progression, or side effects of treatment;
-or-
2 or more stable chronic illnesses;
and a level 5 visit requires:
1 or more chronic illnesses with severe exacerbation, progression, or side effects of treatment;
-or-
1 acute or chronic illness or injury that poses a threat to life or bodily function
In terms of Risk:
A level four visit, for example:
- Prescription drug management
A level five visit, for example:
- Drug therapy requiring intensive monitoring for toxicity
So if a patient is on chronic opioid therapy, it seems like a level four visit is very easy to meet. The question is does prescription opioid management with evaluation for toxicity qualify for a level 5 visit? Probably not - guessing that's more for drugs that have a narrow therapeutic window and require continuous blood level monitoring.
But even for problems addressed qualifying for a level 5 doesn't seem that much of a stretch - a patient that has known radiculopathy with severe exacerbation of symptoms or even a patient that has had lumbar RFA in the past and the pain begins to return in a severe nature. Is that a level 5? If radiculopathy limits your ability to walk, is that a threat to bodily function?